IJOHNS  Vol.4 No.2 , March 2015
A Comparative Study on Efficacy of Fludrocortisones versus Glucocorticoids and Vasodilators in the Treatment of Idiopathic Sensorineural Cochlear Hearing Loss
Introduction and Objectives: The idiopathic sensorineural cochlear hearing loss is one of the most frequent human sensory deficits and there is no specific drug therapy for it. The possible hearing recovery is related with the reestablishment of normal ionic homeostasis of the endolymph controlled by the mineralocorticoid as could be demonstrate experimentally. The purpose of this clinical trial was to confirm the efficacy of mineralocorticoids to the recovery of hearing level in patients suffering idiopathic sensorineural hearing loss (SNHL) against the glucocorticoids and vasodilator drugs. Material and Methods: The research lasted three months and involved 90 patients allocated into four different groups: Placebo group, consisted of 20 patients (10 men and 10 women); the group consisting of 22 patients treated with glucocorticoid therapy (12 men and 10 female); the group treated with mineralocorticoid therapy encompassed 26 patients (13 males and 13 females) and the group of vasodilators formed by 22 patients (12 men and 10 women). The level of hearing loss was estimated by the tests Liminal Tone Audiometry (LTA) and Auditory Brainstem Response (ABR). Results: The main features in this research were overall better response in improving the hearing level with the mineralocorticoid therapy. This improvement in hearing levels was greater in women than in men, and a higher response was found in the left ear regardless of patient’s gender. Conclusions: The hearing gain was significantly superior in the mineralocorticoids group followed by the glucocorticoids group whereas the response to vasodilators was lesser and with no statistical significance.

Cite this paper
López-Campos, D. , López-Aguado, D. , Campos-Bañales, E. , Serdio-Arias, J. and García-Sáinz, M. (2015) A Comparative Study on Efficacy of Fludrocortisones versus Glucocorticoids and Vasodilators in the Treatment of Idiopathic Sensorineural Cochlear Hearing Loss. International Journal of Otolaryngology and Head & Neck Surgery, 4, 115-123. doi: 10.4236/ijohns.2015.42021.
[1]   Berretini, S., Ravecca, F., Forli, F., Sellari-Franceschini, S. and Piragine, F. (1998) Diagnostic and Therapeutic Approach to Progressive Sensorineural Hearing Loss. Acta Otorhinolaryngologica Italica,18, 87-94.

[2]   Yamasoba, T., Lin, F.R., Someya, S., Kashio, A., Sakamoto, T. and Kondo, K. (2013) Current Concepts in Age-Related Hearing Loss: Epidemiology and Mechanistic Pathways. Hearing Research,16, 95-105.

[3]   Zahnert, T. (2011) The Differential Diagnosis of Hearing Loss.Deutsches Arzteblatt international, 108, 433-444.

[4]   Sekiya, T., Hatayama, T., Shimamura, N. and Suzuki, S.(2000) An in Vivo Quantificable Model of Cochlear Neuronal Degeneration Induced by Central Process Injury. Experimental Neurology, 161, 409-502.

[5]   Fish, U., Nagahara, K. and Pollak, A. (1984) Sudden Hearing Loss Circulatory. American Journal of Otolaryngology, 5, 488-491.

[6]   Kansy, L., Ozkarakas, H., Efendi, H. and Okar, I. (2011) Protective Effects of Pentoxifylline and Nimodipine on Acoustic Trauma in Guinea Pig Cochlea. Otology Neurotology,32, 19-25.

[7]   Polon, Y.G., Humli, V., Andó, R., Aller, M., Horváth, T., Harnos, A., Tamás, L., Vizi, E.S. and Zelles, T. (2014) Protective Effect of Rasagiline in Aminoglycoside Ototoxicity. Neuroscience, 265, 263-273.

[8]   Trune, D.R. and Canlon, B. (2012) Corticosteroid Therapy for Hearing and Balance Disorders. Anatomical Record,295, 1928-1943.

[9]   Rita Fetoni, A., Bartolo, P., Eramo, S.L., Rolesi, R., Pacielo, F., et al.(2013) Noise-Induced Hearing Loss (NIHL) as a Target of Oxidative Stress-Mediated Damage:Cochlear and Cortical Responses Alter an Increase in Antioxidant Defense. The Journal of Neuroscience, 33, 4011-4023.

[10]   Rarey, K.E. and Curtis, L.M. (1996) Receptors for Glucocorticoids in the Human Inner Ear. Otolaryngology—Head and Neck Surgery, 115, 38-41.

[11]   Sinha, P.K. and Pitovsky, D.Z. (1995) 3-H-Aldosterone Bingind Sites (Type I Receptors) in the Lateral Wall of the Cochlea: Distribution Assessment by Quantitative Auto Radiography. Acta Oto-Laryngologica, 115, 643-647.

[12]   Jin, D.X., Lin, Z., Lei, D. and Bao, J.(2009) TheRole of Glucocorticoids for Spiral Ganglion Neuron Survival.Brain Research,1277, 3-11.

[13]   Trune, D.R. and Kempton, J.B. (2001) Aldosterone and Prednisolone Control of Cochlear Function in MRL/MpJ-Fas(lpr) Autoimmune Mice. Hearing Research, 155, 9-20.

[14]   Trune, D.R., Kempton, J.B. and Gross, N.D. (2006) Mineralocorticoid Receptor Mediates Glucocorticoid Treatment Effects in the Autoimmune Mouse Ear. Hearing Research, 212, 23-32.

[15]   Trune, D.R., Kempton, J.B., Harrison, A.R. and Wobig, J.L. (2007) Glucocorticoid Impact on Cochlear Function and Systemic Side Effects in Autoimmune C3MRL-Fask or and Normal C3H-Hej Mice. Hearing Research, 226, 209-212.